Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway

Abstract

Regulatory effect of puerarin on bladder cancer T24-cell apoptosis and its possible mechanism were investigated. The experimental subjects were divided into the experimental group, the control group and the blank control group, and the cell inhibition rates after treatment were detected, respectively. Then, subjects were further divided into the control group, the puerarin group (treated with puerarin), the agonist group [treated with silent information regulator 1 (SIRT1) agonist SRT1720], the inhibitor group (treated with SIRT1 inhibitor EX527) and the combination group (treated with SRT1720, and then with puerarin). Apoptosis in each group was detected via flow cytometry, and the expression of apoptosis-related proteins, and SIRT1 and p53 proteins in each group was detected via western blotting. Moreover, the expression of SIRT1 and p53 messenger ribonucleic acid (mRNA) was detected via reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The inhibition rate of bladder cancer T24 cells was significantly increased after treatment with puerarin at different concentrations. Compared with those in the normal control group, the inhibition rates at 24, 48 and 72 h after treatment with puerarin were significantly increased (p<0.05). Compared with those in the control group, the apoptosis rate of T24 cells was remarkably increased after treatment with different doses of puerarin or EX527, and the expression level of apoptosis-related protein Bcl-2-associated X protein (Bax) was also significantly increased, but the expression level of B-cell lymphoma 2 (Bcl-2) was decreased, and both the protein and mRNA expression levels of SIRT1 and p53 also significantly declined. Compared with those in the puerarin group, the apoptosis rate in the combination group was decreased, and the expression level of apoptosis-related protein Bax was also significantly decreased, but the expression level of Bcl-2 was increased, and SIRT1 and p53 protein expression levels were also remarkably increased. Puerarin can inhibit the proliferation of bladder cancer T24 cells and induce apoptosis, and the possible mechanism is related to the inhibition of SIRT1/p53 signaling pathway.

Long noncoding RNA HULC accelerates the growth of human liver cancer stem cells by upregulating CyclinD1 through miR675-PKM2 pathway via autophagy

“…A study shows that SIRT1 enhances the metabolic flexibility [41]. Moreover, SIRT1 promotes glucose transporting [42] and inhibits apoptosis of cancer cells [43]. Our present results are consistent with these reports.…”

Puerarin induces apoptosis in prostate cancer cells via inactivation of the Keap1/Nrf2/ARE signaling pathway

“…To date, many natural occurring products have drawn extensive attention as anticancer agents in the management of cancer development, because of their potential tumor selectivity and low cytotoxicity [11]. Puerarin (PEU), a much famous isoflavone-C-glycoside, is the principal bioactive ingredient from the traditional Chinese herb Radix puerariae, which owns a wide range of biological activities, including cardioprotection, neuroprotection, anti-inflammatory, antioxidant, alleviating pain, inhibiting alcohol intake, regulation of bone metabolism and reduction of intraocular pressure [12][13][14]. Furthermore, an increasing body of evidence has demonstrated PEU also showed anticancer effects in a variety of cancer cell lines, such as lung cancer [15], cervical cancer [16], esophageal cancer [17], bladder cancer [18], gastric cancer [19], colon cancer [20], and so on.…”

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis

“…Previous studies have reported that the majority of drugs exert their anti-cancer effects via inducing apoptosis of tumor cells. 28,30,31 In addition, Zhang et al 32 revealed that bortezomib triggered cell apoptosis in cervical cancer cells. Bruning et al 23 further reported that bortezomib also triggered apoptosis in ovarian cancer cells.…”